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Gene expression dataCM) is a leading cause of heart failure (HF) and cardiac transplantations in
Western countries. Single-source gene expression analysis studies have identiﬁed potential disease
biomarkers and drug targets. However, because of the diversity of experimental settings and relative lack
of data, concerns have been raised about the robustness and reproducibility of the predictions. This study
presents the identiﬁcation of robust and reproducible DCM signature genes based on the integration of
several independent data sets and functional network information. Gene expression proﬁles from three
public data sets containing DCM and non-DCM samples were integrated and analyzed, which allowed the
implementation of clinical diagnostic models. Differentially expressed genes were evaluated in the context of
a global protein–protein interaction network, constructed as part of this study. Potential associations with HF
were identiﬁed by searching the scientiﬁc literature. From these analyses, classiﬁcation models were built
and their effectiveness in differentiating between DCM and non-DCM samples was estimated. The main
outcome was a set of integrated, potentially novel DCM signature genes, which may be used as reliable
disease biomarkers. An empirical demonstration of the power of the integrative classiﬁcation models against
single-source models is also given.
© 2008 Elsevier Inc. All rights reserved.Dilated cardiomyopathy (DCM) is a leading cause of heart failure
(HF) and cardiac transplantations in Western countries [1,2]. In DCM,
the heartmuscle becomes enlarged, making the pumping of blood less
efﬁcient to vital organs. Gene expression studies have offered insights
into the etiology of this disease [2–5]. For example, Barth et al. [2]
analyzed gene expression patterns related to DCM and identiﬁed
speciﬁc gene regulatory relationships relevant to this disease condi-
tion. King et al. [3] analyzed the gene expression of samples with
distinctive HF histological grading and identiﬁed genes, as well as
speciﬁc biological pathways, associated with the disease. Wittchen et
al. [4] analyzed gene expression proﬁles of human inﬂammatory
cardiomyopathy and suggested novel therapeutic targets. Camargo
and Azuaje [6] integrated gene expression analysis with a protein–
protein interaction (PPI) network in human heart failure to investigate
biological responses in experimental DCM. However, it remains
uncertain whether the integration of those independent data sets
may improve systems-level knowledge and support potential clinicalart failure; PPI, protein–protein
d; CP, class predictor; PAM,
teins; HPRD, human protein
, inferred automatically; LOO,
nce analysis of microarray.
l rights reserved.applications. Moreover, there are concerns in connection to the
reproducibility of prediction results based on single-source analyses.
Furthermore, there is a need to exploit available public data to aid in
the translation of biomedical research from bench to bedside.
Themain hypothesis of this study is that the integration of publicly
available data and other information sources may support the iden-
tiﬁcation of common, potentially relevant (and reproducible) disease
biomarkers [7,8]. Barth et al. [2] addressed a similar concern. However,
in their study data were not integrated but analyzed separately. Zhan
et al. [9] integrated three data sets from breast cancer. The results of
the latter study led to the conclusion that data integration increases
predictive analysis and reduces the number of false positives.
To probe our hypothesis, the following sequence of analyses was
carried out: (a) three published microarray data sets, containing
human DCM and non-DCM samples, were integrated; (b) signiﬁcant
expression patterns were analyzed; and (c) potential candidate
disease signature genes were identiﬁed. In parallel, for comparison
purposes, known associations with heart failure (KHF) were retrieved
from public databases [9]. The query constraint was based on the
keywords previously used by King et al. [3] on studies of heart failure.
Candidate genes and KHF were analyzed in the context of a global
human heart failure PPI network to discover responses not identiﬁed
by the expression analysis alone. The potential novelty and relevance
of the key genes identiﬁed from the previous analyses were estimated
by large-scale text-mining analyses. In addition, automated
Table 1
Classiﬁcation accuracy from independent evaluation when the expression vectors of all
genes or of CP genes only were used as model inputs
Learning set Evaluation set % Classiﬁcation accuracy
All genes CP
D1–D2 D3 81 89
D1–D3 D2 64 89
D2–D3 D1 100 100
Classiﬁers were built based on pairwise combination of the D1, D2, and D3 data sets. The
data set not involved in the combination was used for independent evaluation.
405A. Camargo, F. Azuaje / Genomics 92 (2008) 404−413classiﬁcationmodels were built to distinguish between DCM and non-
DCM samples. Statistical comparisons between integrated vs single-
source classiﬁcation models were implemented. Finally, novel disease
signature genes were selected by evaluating outputs produced by each
of the procedures previously mentioned. Based on an integrative
ranking of the preceding outcomes, a list of potentially novel signature
genes is presented, together with speciﬁc biological processes that
appear to be signiﬁcantly altered during DCM development.
Results
This study identiﬁed novel DCM signature genes by performing a
twofold procedure. First, candidate genes were selected from the
expression proﬁle analysis of three microarray data sets from DCM
and non-DCM patients. Second, from this list, potentially signiﬁcant
genes were selected by searching the scientiﬁc literature and by per-
forming data-mining analyses.
Three heterogeneous, lab-independent data sets (from now on
referred to as D1, D2, and D3) with samples from DCM and non-DCM
patients were standardized and normalized. Gene expression ana-
lyses were carried out on individual data sets and on integrated data
sets. The latter sets consisted of the pairwise combination of the
original data sets. Signiﬁcance analysis of microarray (SAM) [11] was
applied to the genes shared by all the data sets (i.e., 5651 in total).
Prediction analysis of microarray (PAM) [12] analyzed pairwise com-
binations of D1, D2, and D3 data sets and identiﬁed class predictor
genes. These analyses produced a list of candidate genes that were
used to build different classiﬁcation models (see Methods). Similar
analyses were also performed on each data set independently (single-
source analyses).
Following the selection of candidate genes, a PPI network was
assembled by including validated gene (or protein)–disease and
protein–protein associations, from Entrez and the Human Protein
Reference Database (HPRD) [13]. The resulting network represents a
knowledge base of HF-relevant interactions. In addition, biological
pathways associated with these genes were mapped onto the
network. A color labeling scheme was used to distinguish between
the different types of proteins and biological pathways that each node
represented in the network. In addition, nodes were classiﬁed ac-
cording to the degree of connectivity (see Methods). The network
analysis allowed us to evaluate signiﬁcant quantitative relationships
between network connectivity and signiﬁcantly differentially ex-
pressed patterns.
Potentially signiﬁcant and novel genes were selected by searching
the scientiﬁc literature. Analyses in the context of Gene Ontology (GO)
[14] were also implemented to identify signiﬁcant biological processes
altered in DCM (see Methods).
Finally, based on a support vector machine (SVM) [15], data clas-
siﬁcation models were assessed. This allowed us to demonstrate the
power of integrative classiﬁers, as well as the identiﬁcation of optimal
combinations of genes for distinguishing between DCM and non-DCM
samples. These tasks provided the basis for the deﬁnition of novel
DCM signature genes for potential diagnostic or drug target prediction
purposes.
Gene expression analysis
Gene expression analysis of DCM and non-DCM samples, from the
combination of the D1 and D2 data sets, identiﬁed 444 signiﬁcantly
differentially expressed (SDE) genes; 207 were up-regulated and 237
were down-regulated in DCM. From the combination of the D1 and D3
data sets, 408 SDE genes were identiﬁed; 199 were up-regulated and
209 were down-regulated in DCM. From the combination of the D2
and D3 data sets, 668 SDE genes were identiﬁed; 255 were up-
regulated and 413 were down-regulated in DCM. In the up-regulated
and down-regulated categories 53 and 32 genes, respectively, over-lapped in the three analyses. In addition, expression analysis of single
sources reported that 22 genes were SDE in D1, 1129 genes were SDE
in D2, and 16 genes were SDE in D3. Only genes HMGN2 and ODC1
were shared by the single-source analyses.
Following gene expression analysis, the PAM technique was used
to identify signiﬁcant class predictor (CP) genes, i.e., genes whose
expression proﬁle vector showed remarkable discrimination capabil-
ity between DCM and non-DCM samples. After cross-validation, PAM
identiﬁed 73 CP genes when the D1 and D2 data sets were combined.
Similarly, in the integrated analysis of the D1 and D3 data sets, 53 CP
genes were identiﬁed. In the integration of the D2 and D3 data sets, 55
CP genes were identiﬁed. When results were compared, it was ob-
served that the genes HMGN2 (high-mobility group nucleosomal
binding domain 2), HTRA1 (HtrA serine peptidase 1), MDFIC (MyoD
family inhibitor domain-containing), ODC1 (ornithine decarboxylase
1), and SEC31A (SEC31 homolog A) were shared by the outcomes of
the three analyses. PAM of single sources identiﬁed 47 CP genes from
D1, whose classiﬁcation performance was 100%; 3 CP genes from D2,
whose classiﬁcation performance was 96%; and 36 CP genes from D3,
whose classiﬁcation performance was 96%. These single-source
analyses did not report common CP genes. Regarding the HMGN2
and ODC1 genes, the expression analysis performed above showed
that they were also up-regulated in DCM.
Once CP genes were identiﬁed, their prediction strength was
statistically validated further by using the corresponding data set not
included in the integrative PAM as an independent evaluation set.
Table 1 shows improvement in classiﬁcation performance whenever
the expression vector of CP genes was used as model input only. When
the classiﬁer was built based on the pairwise combination of the D1
and D3 data sets, the overall classiﬁcation accuracy (non-DCM vs
DCM) on the D2 data (used as an independent evaluation) was higher
than when all the genes were involved (89% vs 64%). Regarding the
evaluation of a single source, a similar evaluation procedure was
performed, i.e., the classiﬁer was composed of one data set and the
remaining data sets were used for independent evaluation, one at a
time. Results of these analyses showed that, when all the genes were
used as model inputs, the overall classiﬁcation accuracy (non-DCM vs
DCM) was below 64% on the corresponding data set used for
independent evaluation. When CP genes were used as model inputs
only, the results differed as follows. When the classiﬁer was built
based on the D1 or D3 data sets, classiﬁcation accuracy on the data
sets D3 and D1, respectively, was above 93%. When the classiﬁer was
built based on D2, classiﬁcation accuracy on the corresponding eva-
luation set, D1 or D3, was below 70%.
Gene Ontology analysis
The list of common SDE genes, which also contain CP genes, was
analyzed in the context of GO. This analysis identiﬁed the following
GO biological processes as signiﬁcantly overrepresented: phosphor-
ylation, protein amino acid phosphorylation, positive regulation of
epithelial cell proliferation, epithelial cell proliferation, and regulation
of epithelial cell proliferation. Other studies have identiﬁed the
alteration of these processes whenever there is an ongoing risk of
406 A. Camargo, F. Azuaje / Genomics 92 (2008) 404−413heart failure [17,18]. GO analysis of CP genes reported no signiﬁcantly
overrepresented biological processes.
PPI network analysis
The PPI network (Fig. 1A) consisted of nodes representing
proteins, their interaction partners, and the biological pathways
associated with their encoding genes. Some of the nodes repre-
sented proteins encoded by signiﬁcantly differentially expressed
genes obtained from the previous expression pattern analyses. In
total, the network includes 2227 protein–protein interactions and
1515 nodes corresponding to proteins. In the above section on gene
expression analysis of pairwise combinations of data sets, we
reported the overlap of 85 SDE genes. Of this total, 53 genes were
up-regulated in DCM and 32 genes were down-regulated in DCM.
However, when they were mapped onto the network, only 45
genes (27 up-regulated and 18 down-regulated genes in DCM)
could be represented by a node. This is because the proteins
encoded by some of those genes were not associated with at least
one interacting protein partner. In the case of CP genes, only 3 of
them were represented by a node in the network: HMGN2, HTRA1,
and ODC1. The network also contained 71 nodes representing
proteins encoded by KHF genes. How the KHF genes were obtained
is summarized under Methods.
According to the node categorization scheme described under
Methods, 2.1% of genes were represented by network hubs or
superhubs (only seven hubs represented 7 signiﬁcantly differentially
expressed genes). In contrast, 97.8% of the genes were represented by
either network peripheral-A or network peripheral-B nodes (30
peripheral-A and 9 peripheral-B nodes represented 39 signiﬁcantly
differentially expressed genes). Details are shown in Table 2.Fig. 1. PPIs corresponding to (A) the global network, (B) DYNLL1's network, and (C) PICK1's ne
by red nodes. Down-regulated genes are represented by green nodes. KHF genes are rep
represented by nodes in purple, if they were present across D1, D2, and D3 data sets, and inExamples of potentially relevant associations are described as
follows. DYNLL1 (dynein, light chain, LC8-type 1) is a protein re-
presented by a network hub (Fig. 1B), and TERF1 (telomeric repeat
binding factor) is represented by a network peripheral-A. These
two proteins interact through ZHX1 (zinc ﬁngers and homeoboxes
1). According to gene expression analysis, both DYNLL1 and TERF1
encode signiﬁcantly differentially expressed genes (up-regulated in
DCM). Also, PICK1 (protein interacting with PRKCA1) represents a
network hub (Fig. 1C). Currently, PICK1 is not known to be
associated with HF. However, it intervenes in the protein amino
acid phosphorylation and protein kinase C activation biological
processes [16], which are involved in the progression of heart
failure [3,4].
Only 33 KHF genes had a corresponding transcript in the gene
expression data set, and only 1 of these genes, CCL2, was signiﬁcantly
differentially expressed (down-regulated in DCM). In addition, 656
genes that encoded other proteins' interaction partners in the network
had a corresponding transcript in the gene expression data set and
were not signiﬁcantly differentially expressed.
Network connectivity versus signiﬁcant gene expression patterns
This section of the study integrated gene expression analysis
results, in the form of di values, obtained from the SAM, with the
PPI network. The aim was to describe potential signiﬁcant relation-
ships between network connectivity and gene expression patterns
(as described in Methods). Results were as follows: when the focus
was on signiﬁcantly differentially expressed genes only, we found
that genes represented by network superhubs and hubs tend to
have lower range of di values. In Fig. 2A genes with those
characteristics are shown on the far right of the plot. Furthermore,twork. All PPIs were retrieved from the HPRD. DCM up-regulated genes are represented
resented by nodes in yellow. Other genes encoding interacting partner proteins are
teal, if they were not common across D1, D2, and D3 data sets.
Fig. 1 (continued).
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higher range of di values than hubs and superhubs. When proteins
encoded by non-signiﬁcantly differentially expressed genes were
assessed, we found similar results (Fig. 2B). However, neither super-
hubs nor hubs were found. In fact, only two genes (EGFR and SRC)
were represented by nodes with 11 and 12 interactions, respectively.
The other genes were represented by nodes that had fewer than 10
interactions. Interestingly, EGFR is involved in more than 10 bio-
logical pathways; some of them are the MAPK signaling pathway
and hemostasis, which play important roles in the development of
DCM [19].
Extracting signiﬁcant associations based on large-scale literature mining
Multiple searches on the scientiﬁc literature were performed to
identify known associations with DCM or HF. The SDEs, including CP
genes, were part of the query list, together with those found to be
relevant in the PPI network analysis. Therefore, each of these genes'
IDs was used to query the PubMed information source, through the
Agilent literature search tool [20]. The search was constrained by
the keywords “heart failure,” “dilated cardiomyopathy,” and “cardi-
ovascular diseases.” According to these parameters, Table 3 shows a
list of gene IDs that, to date, have not been associated with the
disease target. Additional details about the genes are also provided,
such as IPs, node hierarchy, and average “d” value. The genes
DYNLL1, TERF1, and PICK1 are again highlighted, as well as the CP
genes HMGN2, HTRA1, and ODC1. These three genes have also been
associated with tumor-related disorders [16]. In future research, it
may be interesting to investigate why these genes show evidence
of overregulation in samples obtained from patients with a DCM
condition.Evaluation of diagnostic models
This part of the study investigated the optimal combination of gene
expression patterns to differentiate between DCM and non-DCM
samples. As described in Methods, the SVM technique was chosen to
construct these classiﬁers and study optimal combinations of genes as
model inputs. The area under the curve (AUC) of the receiver
operating characteristic (ROC) curve was used to estimate class
prediction performance. Different comparative schemes for testing
and independent evaluations were implemented. In the pairwise
combination of individual data sets for building and cross-validating
classiﬁers (i.e., D1–D2, D1–D3, and D2–D3), the best class prediction
performance was obtained when CP genes were used as the inputs to
the classiﬁer only. Using leave-one-out (LOO) cross-validation,
estimated AUCs for each pairwise combination were 0.64, 0.48, and
0.57 (Table 4). In contrast, when other classiﬁcation models (other
groups of genes, such as SDE, were used as the inputs to the classiﬁer)
were assessed, prediction performance declined. For instance, when
the genes listed in Table 3, including three CP genes, were used as the
inputs to the classiﬁer, prediction performance declined. AUCs for each
pairwise combination were 0.51, 0.23, and 0.28. When all SDE genes
were used as inputs, estimated (LOO) AUCs per pairwise combination
of data sets were 0.46, 0.11, and 0.17. We also found that in general, the
classiﬁcation accuracy of non-DCM and DCM samples was above 90%.
Classiﬁcation models were also independently evaluated on the data
set left out from each data integration experiment. Table 4 shows
results from these analyses, which in general conﬁrm the predictive
ability of the CP genes. For example, without exception, when CP
genes were the inputs to the classiﬁers, estimated (LOO) AUCs were
above 0.99. Surprisingly, when KHF genes were the inputs to the
classiﬁer, estimated (LOO) AUCs were below 0.8; recall that KHF genes
Fig. 1 (continued).
Table 2
Summary of node populations according to connectivity
Hierarchy SDE NSDE KHF Total
Superhubs 0 0 3 3
Hubs 7 0 22 29
Peripheral-A 30 412 43 485
Peripheral-B 9 986 3 998
Total 46 1398 71 1515
The number of nodes within each category present in the interaction network is shown.
SDE, signiﬁcantly differentially expressed genes; NSDE, non-signiﬁcantly differentially
expressed genes; KHF, known HF genes retrieved from the Entrez database [9]. PPIs
were obtained from the HPRD [13].
408 A. Camargo, F. Azuaje / Genomics 92 (2008) 404−413have been previously associated with HF. Fig. 3A shows ROCs
corresponding to the evaluation of the pairwise integration of the
D1 and D2 data sets (LOO cross-validation results). The ROC in Fig. 3B
corresponds to the evaluation of the integrated classiﬁcation model
D1–D3 on an independent evaluation set, D3.
Single-source classiﬁers were also evaluated independently (i.e.,
models trained and tested using D1, D2, and D3 independently).
Table 5 reviews results obtained when expression proﬁles of SDE, CP,
or KHF genes from each data set were used as inputs to the SVM
classiﬁer. In general, class prediction performance was weaker than
that achieved by the integrated data sets. For example, Table 5 and Fig.
3B show ROCs and AUCs respectively, for each classiﬁcation model,
when the classiﬁer was built on the D2 data set (corresponding
evaluation sets were D1 and D2). Low performance may be explained
by the relative lack of data within the single-source models in
comparison to the integrated models. For example, the relation of
samples between non-DCM and DCM in D3 was 25% (7) to 75% (20),
respectively. Estimated (LOO) AUCs were lower than in the other two
groups. Conversely, the relation of samples between non-DCM and
DCM in D3 was 54% (15) to 13% (20), respectively. Estimated (LOO)
AUCs were higher than in the other two groups. Note that according to
the results obtained from PAM, on the analysis of a single-source data
set, class prediction performance of CP genes was on average above
96%. This may seem to contradict the results obtained with the SVM.
As in the previous integrative analysis, whenmodel evaluationwas
based on a single source, estimated (LOO) AUCs improved (Table 5).
However, here, some classiﬁcation models based on CP genes could
not be evaluated (indicated by the word NAN). This happened because
CP genes were not common among learning and evaluation sets. In thecase of classiﬁcation models based on SDE genes, the average es-
timated (LOO) AUC of the corresponding independent evaluations was
above 0.9. As for KHF genes, the average estimated (LOO) AUC of the
corresponding independent evaluations was below 0.8. These results
conﬁrmed that estimated AUCs improved whenever the number of
samples in the learning set increased. In other words, single-data-
source analysis may produce several false positives owing to
evaluation methodology bias and overall lack of data. Results also
suggest that measures such as classiﬁcation accuracy may convey
unreliable results and that other measures that estimate false
discovery rates (FDR) and AUCs should be favored. Therefore, it is
usual to ﬁnd that genes regarded as signiﬁcant biological markers may
be restricted or biased to a particular microarray data set that was
hybridized under special conditions. This problem was highlighted
early on by Ancona et al. [21], who analyzed cancer-related microarray
Fig. 2. Plots of t statistic (di) representing the score for gene i vs the number of interacting partners (IPs), expressed on the log2 scale, associated with the protein encoded by gene i.
The plots show the average of di values obtained in each of the three gene expression analyses. (A) Signiﬁcantly differentially expressed genes. (B) Non-signiﬁcantly differentially
expressed genes.
409A. Camargo, F. Azuaje / Genomics 92 (2008) 404−413data and found that the expression proﬁle of previously reported CP
genes could not be replicated in their own study. This underscores the
need for integrating several data sources for potentially rendering
more accurate and less biased results.
Fig. 3C shows ROCs corresponding to the evaluation of models
based on a single source. The ROCs in Fig. 3D were obtained when the
classiﬁer was built using the D1 data set, and for independent
evaluation the sets D2 and D3 were used.
Potential most signiﬁcant biomarkers
The preceding evaluation procedure helped to identify a list of
candidate genes that could be seen as possible disease signatures. The
overall results suggested that the following genes could be novel DCM
signature genes, which were also signiﬁcantly differentially expressed
in the integrative analysis: PICK1, DYNLL1, ODC1, HTRA1, and HMGN2.
ODC1, HTRA1, and HMGN2 were identiﬁed as class predictor genes,
which were the inputs to the most successful disease classiﬁcation
model. However, the proteins these three genes encode were asso-ciated with a few IPs. Although not selected as CP genes, PICK1 and
DYNLL1 encode proteins associatedwith several IPs. Finally, the search
performed on public data sources suggested that none of these ﬁve
genes has been previously associated with heart failure. Other genes
that are suggested as potentially interesting for future experimental
and computational analyses are MORF4L2, MEF2D, TMEM66, USP11,
and TRIP12. These genes were all signiﬁcantly differentially expressed.
In addition, searches in the scientiﬁc literature suggested that none of
these ﬁve genes has been previously associated with heart failure.
Discussion
Heart failure, one of the main causes of morbidity and mortality in
the world [1], is a polygenic disease whose etiology stems from
complex genetic, environmental, and lifestyle factors. Various re-
search efforts have aimed to dissect the molecular mechanisms of this
disease [7,8]. To date, a number of disease signature genes have been
reported as the result of (single-source) gene expression analyses [2–
6,8], and a fair amount of microarray expression data sets have been
Table 3
Potential novel gene–HF associations
Gene IPs Hierarchy Average d
DYNLL1 5.86 Hub 2.8998
PICK1 5.00 Hub −2.6123
COPB1 4.09 P-A 2.5357
TERF1 4.00 P-A 2.3909
MEF2D 3.32 P-A −2.9648
DYNLT1 3.17 P-A 2.3975
TFE3 3.00 P-A −2.9414
MORF4L2 2.58 P-A 2.9716
NR2F6 2.58 P-A −2.8883
HMGN2a 2.58 P-A 3.6840
TRIP12 2.32 P-A 3.1072
MATR3 2.00 P-A 2.7881
HMG20B 2.00 P-A −2.4366
ZBTB7A 2.00 P-A −2.7172
HTRA1a 1.58 P-A 3.7141
PUM1 1.00 P-A 2.6043
STK38L 1.00 P-A 2.8791
USP11 1.00 P-A 3.0334
ODC1a 1.00 P-A 3.7095
GOLGA7 0.00 P-B 2.3191
MKRN1 0.00 P-B 2.6822
TMEM66 0.00 P-B 3.2034
BCKDK 0.00 P-B −2.8296
EIF4EBP2 0.00 P-B −2.4417
GCAT 0.00 P-B −2.8648
IPs (log2). Node hierarchy according to the PPI network (P-A, peripheral-A; P-B,
peripheral-B). The average of (d) values obtained in each of the three gene expression
analyses performed is given.
a CP genes.
Table 4




Learning (AUC) Independent evaluation (AUC)






1 CP 0.64 0.48 0.57 0.99 1.00 1.00
2 KHF 0.51 0.10 0.19 0.79 0.66 0.51
3 SDE 0.46 0.11 0.17 0.93 0.98 1.00
4 SDEnKHF 0.51 0.23 0.28 0.94 0.99 1.00
5 SDEKHF 0.52 0.28 0.38 0.94 0.95 1.00
6 All 0.46 0.11 0.17 0.93 0.98 1.00
The classiﬁer was built on the pairwise combinations of the individual D1, D2, and D3
data sets. Classiﬁcation performance was evaluated through LOO cross-validation. From
those results, ROC curves were plotted and AUCs were estimated. Classiﬁcation models
were also independently evaluated on the data set left out from each data integration
experiment (E). Classiﬁcation models according to the group of genes used as inputs to
the classiﬁer: CP, class predictor genes; KHF, known HF genes; SDE, signiﬁcantly
differentially expressed genes; SDEnKHF, signiﬁcantly differentially expressed+non-
KHF genes; SDEKHF, signiﬁcantly differentially expressed+KHF genes.
410 A. Camargo, F. Azuaje / Genomics 92 (2008) 404−413uploaded into public databases. Despite these efforts, results from
each study may be biased and may vary widely due to the in-
dependent experimental conditions being deﬁned. Therefore, a key
challenge is to ﬁnd ways to integrate such information to facilitate the
discovery of disease-speciﬁc knowledge andmore powerful predictive
targets. In a recent paper, Zhan et al. [10] held that the integration of
microarray data gives more analytical power and reduces the false
discovery rate. As a result, the probability of identifying more bio-
logically meaningful patterns is high. This study, which focused on
DCM, integrated independent microarray data sets and other
information sources to add power to the data-mining techniques
implemented. The methodology aimed at the identiﬁcation of po-
tentially novel and powerful DCM signature genes.
The ﬁrst gene expression analysis phase of this study identiﬁed a
total of 85 SDE genes, common to all the single-source analyses. Two
of those genes, ODC1 and HMGN2, were also previously identiﬁed by
Barth et al. [2] as signiﬁcantly differentially expressed in the analysis
of independent data sets. However, a further analysis carried out by
them found that HMGN2 could not be regarded as a class predictor
gene. The second stage of our study selected CP genes, i.e., those SDE
genes whose expression vector showed signiﬁcant differentiation
between DCM and non-DCM samples based on PAM. This analysis
identiﬁed 5 genes, HMGN2, ODC1, HTRA1, MDFIC, and SEC31A, whose
expression patterns showed signiﬁcant differences between the two
experimental conditions being evaluated (non-DCM and DCM).
Results were supported by further testing procedures. Using a
network-based analysis strategy that we published elsewhere, we
found additional relevant biomarkers when we assessed microarray
data in the context of a global HF PPI network [6]. Also we found that
some of our candidate CP genes encoded proteins associated with no
interacting partners (i.e., MDFIC and SEC31A). Similarly, the remaining
CP genes encoded proteins associated with just a few interacting
partners (network peripheral-B). Also, we found non-CP genes en-
coding proteins associated with several other interacting partners
(e.g., DYNLL1, ERBB2, and PICK1), i.e., network hubs.We conﬁrmed the
potential novelty of some of these biomarkers, such as DYNLL1 andPICK1, when querying public information sources to identify known
associations with heart failure or DCM. Various classiﬁcation models
were also implemented, and their classiﬁcation performance was es-
timated. Results led to the conclusion that whenever CP genes were
the inputs to the classiﬁer, a classiﬁer with high AUCs was obtained.
Moreover, whenever KHF genes were the inputs to the classiﬁer, the
estimated AUCs were in general low. Gathering and evaluating all
these results led us to select a pool of genes and suggest them as
possible novel DCM signature genes. It also conﬁrmed that KHF genes
may not be so interesting in other independent studies, because these
studies may have used other experimental settings (i.e., type of tissue
samples, data-mining approach, and microarray technology used to
hybridize RNA). We probed the latter when in the evaluation of
models based on a single source, we built the classiﬁer on D3 and used
D1 as an independent evaluation set. Because these two data sets were
obtained from similar microarray technologies, CP genes overlap.
Therefore, learning and evaluation of the classiﬁcation model based
on CP genes were possible. What it is more, the best estimated AUC
(0.99) was obtained here.
This study conﬁrms the importance of integrating independent
data sets and their subsequent evaluation against other information
sources. In this way more meaningful information can be discovered
as opposed to that obtained from single-source and traditional
analyses. This methodology may lead to the identiﬁcation of poten-
tially inﬂuential genes not identiﬁed when single studies were carried
out in the ﬁrst place. For example, the gene HTRA1 was not identiﬁed
as an SDE by any of the expression analyses performed on each single
source. However, this gene was selected as a key biomarker based on
the combination of gene expression and network analysis. HTRA1 is a
regulator of cell growth and intervenes in the process that regulates
the availability of insulin-like growth factors, which has already been
associated with HF. In addition, data integration may contribute to
lessening the degree of false positives that are bound to be found
when single data sets are assessed. Note, for instance, that in the
independent evaluation of single sources, the PAM class prediction
rate, based on CP genes, was on average above 96%. However, when
the same group of CP genes was the input of independent clas-
siﬁcation models and evaluated on independent data sets, class pre-
diction rate was severely degraded in most cases.
The proposed prediction models were evaluated using model cross-
validation, aswell as published literature and external knowledge bases.
These strategies have become standard in the initial phases of model
design and evaluation of biomarkers and diagnostic models. However,
in the longer term, the potential clinical relevance of biomarker dis-
covery and new diagnostic models will be truly estimated by
Fig. 3. ROC curves derived from LOO cross-validation and corresponding independent evaluation of (A) the model based on pairwise combination of D1 and D2; (B) the model
evaluated on D3; (C) the model based on the single-source D1; and (D) the model evaluated on D2 and D3, independently.
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research groups. This paper reports new testable hypotheses, in the
form of biomarkers and computational models, which may be inde-
pendently evaluated. Furthermore, it offers a new prediction model
methodology, which may be adapted to other clinical domains.
One aspect to be covered in the future is the analysis of responses on
HF-speciﬁc biological pathways, on a PPI network. This type of analysis
may help us to visualize and interpret interesting stimulus–response
activities that take place in HF-associated biological pathways.
Methods
Microarray data analysis
Three microarray data sets generated by independent studies on DCM were
obtained from the Gene Expression Omnibus [22], Accession Nos. GDS2205, GDS2206,
and GDS1362 (referred as to D1, D2, and D3 herein). D1, oligo array, was composed of 12
samples: 5 and 7 samples were obtained from nonfailing hearts and DCMheart patients,respectively. D2, cDNA array, was composed of 28 samples: 15 and 13 samples were
obtained from nonfailing hearts and DCM heart patients, respectively. D3, oligo array,
was composed of 37 samples: 7, 20, and 10 samples were obtained from nonfailing
hearts, DCM heart, and ischemic cardiomyopathy (ICM) patients, respectively. The latter
ICM pool of samples was discarded as the disease condition was not involved in this
study. Data sets were originally available in log scale.
Data preprocessing
Probe sets with absent calls in more than 50% of their transcripts were discarded.
Transcripts of probe sets corresponding to similar Gene IDs were averaged. Common
probe sets among D1, D2, and D3 data sets were selected. In total, 5651were present. Data
sets were normalized per chip and then per gene. Values were transformed using the
mean and standard deviation of the row (per gene) or column (per chip).
Gene expression analysis
Differential gene expression was measured by performing SAM [11]. The algorithm
computes a t statistic (di) representing the score of class differentiation for gene i. Gene
expression differences were considered signiﬁcant if FDR was b0.05 and fold change
Table 5
AUCs representing class prediction performance of different classiﬁcation models
Independent evaluation
No. Classiﬁcation model LOO evaluation of model based on a
single source
Model based on D1
and independently
evaluated on:
Model based on D2
and independently
evaluated on:
Model based on D3
and independently
evaluated on:
D1 D2 D3 D2 D3 D1 D3 D2 D3
1 CP 0.37 0.64 0.45 NAN 0.99 NAN NAN 1.00 NAN
2 KHF 0.40 0.92 0.29 0.67 0.71 0.71 0.39 0.74 0.51
2 SDE 0.48 0.92 0.36 0.98 0.99 1.00 0.99 1.00 1.00
Evaluation was based on a single source, and performance was measured through LOO cross-validation. From those results, ROC curves were plotted and AUCs were estimated. The
data sets not included in the construction and cross-validation of each classiﬁcationmodel were used as evaluation sets. AUCwas estimated. Classiﬁcationmodels, according to group
of genes used as inputs to the classiﬁer: CP, class predictor genes; KHF, known HF genes; SDE, signiﬁcantly differentially expressed genes.
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D2, and D3 were created; DCM and non-DCM samples were separated; and SAM was
applied to each integrated data set. As a measure for comparison, this study analyzed
the expression proﬁle of single data sources. SAM was also used in this part of the
analysis.
PAM [12], a statistical technique for class prediction from gene expression data that
uses nearest shrunken centroids, identiﬁed class predictor genes, i.e., DCM and non-
DCM. For learning purposes, based on 10-fold cross-validation to select optimal
threshold, PAM analyzed the expression proﬁle of DCM versus non-DCM samples of the
pairwise combinations of D1, D2, and D3 data sets. For evaluation purposes, the data set
not involved in each combination was used as the evaluation set. As a measure for
comparison, single data sources were analyzed independently. PAMwas also applied in
this part of the analysis.
A human HF interaction network
A PPI network was assembled by including validated interactions reported for KHF
genes, for proteins encoded by genes included in the gene expression data sets, and for
the biological pathways associated with them. This network is offered as a public
resource of the current status of human HF-relevant interactions (network is provided
on request). The list of KHF genes was obtained from the Entrez database [9]. Entrez
query was restricted by the same set of keywords used in King et al. [3] (i.e., smooth
muscle, endothelial cell, apoptosis, cytokine, and adhesion molecule) and within the
context of human HF. PPIs were retrieved from the HPRD [13]. The HUGO nomenclature
standard was used to deﬁne unique ID identiﬁers.
The PPI network was assembled using a routine written in JAVA, and its structure
was encoded in the SIF format, which can be used by well-known network visualization
tools (e.g., Cytoscape). The product of this assembly was a network composed of 1515
nodes and 4452 interactions. The number of interacting partners ranges from 1 to more
than 100. A color labeling schemewas used to distinguish between the types of proteins
each node represented. Proteins encoded by up- and down-regulated genes (as
predicted in the gene expressiondata)were represented bynodes colored red and green,
respectively. Proteins encoded by class predictor genes were represented by nodes
colored light blue. Proteins encoded by KHF genes were represented by yellow nodes.
Proteins encoded by nonsigniﬁcantly differentiated genes were represented by blue
nodes. Proteins encoded by genes whose expression patternwas not present in the data
set, but which encoded relevant interacting partners in the HF network, were also
represented by blue nodes. Kegg and Reactome pathways were represented by blue and
purple square nodes, respectively.
Nodes in the network were also classiﬁed according to the degree of connectivity,
based on a scheme similar to that used in Lu et al. [23]. Superhubs are represented by
nodes with connectivity degree greater than 100, hubs refer to nodes with connectivity
degree greater than 20 and lower than 100, peripheral-A are nodes with connectivity
greater than 2 and lower than 20, and peripheral-B nodes represent proteins with one
interacting partner only.
Cytoscape version 2.4 [24] was used for network visualization.
Network analysis
Relationships between PPI's network topology and expression proﬁle patterns were
investigated. First analysis focused on genes present in the data sets. Therefore, the
average d value of each gene was compared against the degree of connectivity
associated with the protein they encoded. The second analysis focused on genes not
present in the data sets (but present in the PPI network).
Gene Ontology analysis
Interaction network topology was analyzed in the context of Gene Ontology [14].
Cytoscape-BiNGO [24] was applied to detect signiﬁcantly overrepresented GO
biological processes. Benjamini and Hochberg multiple-test corrections adjusted raw
P values at a signiﬁcance level of b0.05. To increase the level of stringency, GO-IEA
terms were discarded. GO annotations with IEA evidence code refer to annotationsinferred from sequence-based similarity searches, which have not been reviewed by
curators.
Extracting signiﬁcant associations based on large-scale literature mining
To determine which genes, from a group of candidates, were potentially novel in
the area of HF and DCM, the Agilent Literature Search plug-in in Cytoscape [25] was
used. Agilent queries multiple text-based search engines, such as PubMed and OMIM, to
ﬁnd document-based associations between each gene and a keyword (i.e., heart failure
and DCM). When a query is processed, Agilent implements information retrieval and
knowledge extraction and returns the documents (from papers) that match the query.
The retrieval is based on comparing the search term, i.e., gene and disease target,
against abstracts and keywords.
Evaluation of diagnostic models
This section of the study evaluated classiﬁcation models based on two different
schemes: ﬁrst, the classiﬁer was built on the pairwise combinations of D1, D2, and D3
data, and the model was evaluated on the set not involved in the combination. The
second scheme built the classiﬁer on a single data set, and the model was evaluated on
the remaining two data sets, one by one. As for the classiﬁer, the SVM [26] data
classiﬁcation technique was used for this purpose. SVM trained on several classiﬁcation
models used in this study and classiﬁcation performance, through cross-validation, was
estimated. Results led to the selection of the best model. Because of the nonlinearity of
the data, radial basis function (RBF) was used as the kernel. The LOO cross-validation
technique was applied to select optimal RBF parameters and to train classiﬁcation
models, for each testing scheme involved in the study. ROC curveswere used tomeasure
class prediction rate according to the classiﬁcationmodel being evaluated. ROC plots the
false positive rate against the true positive rate and the AUC is estimated. AUC ranges
from0 to 1, which gives an indication of howgood a classiﬁer is. LibSVM [26]was used to
implement the SVM classiﬁer.
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